Abstract:
Objective
To investigate the value of baseline and dynamic changes of peripheral blood neutrophil to lymphocyte ratio （PLR） and platelet to lymphocyte ratio （PLR） in predicting the curative effect and prognosis of patients with hepatocellular carcinoma （HCC） treated with transcatheter arterial chemoembolization （TACE） + Lenvatinib + camrelizumab.
Methods
The clinical data of 119 HCC patients admitted to the First Affiliated Hospital of Bengbu Medical College from January 2020 to February 2023 who received triple therapy of TACE + Lenvatinib + camrelizumab were retrospectively analyzed.The levels of NLR and PLR before treatment and two months after treatment were recorded as NLR0， PLR0， NLR2 and PLR2， respectively.The levels of NLR0， PLR0 and NLR2， PLR2 in the effective group and the ineffective group were compared.According to receiver operating characteristic （ROC） curve， the optimal cut-off values of NLR and PLR were obtained， and used as the basis for grouping high and low.Kaplan-Meier method was used for survival analysis， and Cox proportional risk model was used for univariate and multivariate regression analysis.
Results
According to ROC， the best cut-off points of NLR0， PLR0 and NLR2， PLR2 were 2.10， 134.4 and 2.8， 153.0.The levels of NLR2 and PLR2 in the effective group were significantly lower than those in the ineffective group （P＜0.01）.Univariate and multivariate analysis showed that NLR2，PLR0， and age were correlated with overall survival （all P＜0.05）.Dynamic analysis revealed that the median survival time of the low PLR0 and low PLR2 groups was 29 months， significantly better than the 14 months of the high PLR0 and high PLR2 groups （P＜0.001）； the median survival time of the low NLR0 and low NLR2 groups was 26.5 months， which was better than the 18.1 months of the high NLR0 and high NLR2 groups（P=0.002）.
Conclusion
The baseline values and dynamic changes of peripheral blood NLR and PLR can predict the efficacy and prognosis of patients receiving TACE + Lenvatinib + Camrelizumab.
Key words:
Carcinoma， hepatocellular,
Neutrophil to lymphocytes ratio,
Platelet to lymphocyte ratio,
Curative effect,
Prognosis,
Transcatheter arterial chemoembolization,
Lenvatinib,
Camrelizumab
Bowen Jiang, Chang Shu, Xiangyang Zhao, Tao Tao, Ti Tan. Prognostic value of peripheral blood neutrophil to lymphocytes ratio and platelet to lymphocyte ratio in the combined treatment of unresectable hepatocellular carcinoma through transcatheter arterial chemoembolization + targeted immunotherapy[J]. Chinese Archives of General Surgery(Electronic Edition), 2024, 18(02): 99-105.